Media & PR
Binger Strasse 173
55216 Ingelheim am Rhein
Ingelheim/Germany, 27 November 2009 - Boehringer Ingelheim has concluded its collaboration with Vectura by mutual consent. Under the terms of the agreement, signed in April 2006, Boehringer Ingelheim has worked with Vectura to develop a dry powder multi-dose inhaler. This collaboration has added significantly to Vectura's and Boehringer Ingelheim's intellectual property portfolios.
Having completed the device design phase of the agreement, both Vectura and Boehringer Ingelheim decided that the original terms agreed over three and half years ago no longer reflect the companies’ changing requirements. There is an opportunity to structure more appropriate deal terms should a subsequent agreement be negotiated with Vectura in the future.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2008, Boehringer Ingelheim posted net sales of 11.6 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.
Please be advised
This release is from Boehringer Ingelheim Corporate Headquarters in Germany. Please be aware that there may be national differences between countries regarding specific medical information, including licensed uses. Please take account of this when referring to the information provided in this document. This press release is not intended for distribution within the U.S.A.